Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CRMD vs REPL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

CRMD Overall Winner 6-Pillar Tally: CRMD 4 – 2 REPL Matrix Metrics: CRMD 7 – 3 REPL

As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Replimune Group, Inc. (REPL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin), whereas REPL carries 34.8/100 (SELL) at $19.74 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. REPL 34.8/100 SELL) and 1.22β · 103% Vol risk profile, whereas REPL leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8); meanwhile REPL trades in a Markup technical trend (BREAKOUT options phase, RSI 59.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRMD vs REPL
CRMD NASDAQ Head-to-Head Winner
CorMedix Inc.
Pharmaceutical Preparations
$4.70
-2.59% 1D
Market Cap $370.6M
TTM Revenue $1.01B
Forward P/E 29.5x
Beta / 30D Vol 1.22β · 103% Vol
Unified Composite Score
55.5 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 70.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.1%), weak momentum, RSI 27
RSI-14: 26.8 · SMA20: $6.18 · SMA50: $7.04
REPL NASDAQ
Replimune Group, Inc.
Biological Products, (No Disgnostic Substances)
$19.74
-7.8% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.14β · 104% Vol
Unified Composite Score
34.8 / 100 SELL
Tech 16.0 Fund 44.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.4% over 20 days), RSI 59
RSI-14: 59.2 · SMA20: $18.34 · SMA50: $14.99

6-Pillar Scorecard Institutional Category Breakdown (CRMD 4 – 2 REPL)

Columns: Metric · CRMD · REPL
1. Valuation Multiples CRMD
Forward P/E 29.5x N/M
Trailing P/E 2.4x N/M
PEG Ratio 3.32x N/M
EV / Revenue N/M N/M
2. Growth & Scale REPL
Revenue Growth (YoY) -47.7% +0.0%
Earnings Growth (YoY) +6.7% +0.0%
TTM Revenue (USD) $1.01B N/A
Market Cap $370.6M $2.1B
3. Profitability & Quality CRMD
Gross Margin 87.4% N/A
Operating Margin 41.0% 0.0%
Net Profit Margin 15.5% 0.0%
Return on Equity (ROE) 15.3% -115.8%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) $755M -$246M
Cash Flow Margin 74.6% N/A
Net Cash / Leverage $514M Net Cash $181M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning REPL
Options Structure Phase BREAKDOWN BREAKOUT
Current IV / %ile 53.2% (22nd %ile) 220.4% (23rd %ile)
Put/Call OI Skew 2.32x (Put-Skewed) 0.03x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat CRMD
OpEx & R&D Intensity 46.4% of Rev ($469M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRMD (7) vs REPL (3)
Institutional Metric CRMD REPL Criterion Row Edge
Market Capitalization
Scale
$370.6M $2.1B Larger Scale REPL
Trailing P/E Ratio
Valuation
2.4x N/M Lower Multiple CRMD
Forward P/E Ratio
Valuation
29.5x N/M Lower Multiple CRMD
Revenue Growth (YoY)
Growth
-47.7% +0.0% Higher Growth REPL
Operating Margin (TTM)
Profitability
41.0% 0.0% Higher Margin CRMD
Net Profit Margin
Profitability
15.5% 0.0% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
15.3% -115.8% Higher ROE CRMD
52-Week Range Position
Momentum
1% ($5–$13) 83% ($2–$24) Stronger Trend REPL
Beta / 30D Volatility
Risk Regime
1.22β · 103% Vol 2.14β · 104% Vol Lower Realized Risk CRMD
Unified Institutional Score
Composite Signal
55.5 / 100 (HOLD) 34.8 / 100 (SELL) Higher Composite CRMD
Trailing 12M Revenue (USD)
Operating Scale
$1.01B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.32x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$755M ($514M Net Cash) -$246M ($181M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REPL +115.02 pp
CRMD: -36.38% · REPL: +78.64%
3M Horizon REPL +78.18 pp
CRMD: -44.89% · REPL: +33.29%
6M Horizon REPL +334.65 pp
CRMD: -40.64% · REPL: +294.01%
1Y Horizon REPL +177.81 pp
CRMD: -58.23% · REPL: +119.58%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMD vs REPL. Trailing 12-month operating profitability (CRMD 41.0% vs REPL 0.0%) and valuation multiples (CRMD 29.5x vs REPL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CRMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.01B
Gross Margin87.4%
Op. Margin41.0%
ROE / Fwd P/E15.3% · 29.5x
REPL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-115.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRMD BREAKDOWN
110d in phase · OBV DISTRIBUTION
Current IV 53.2%
IV Percentile 22nd %ile
Put/Call OI Skew 2.32x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
REPL BREAKOUT
99d in phase · OBV NEUTRAL
Current IV 220.4%
IV Percentile 23rd %ile
Put/Call OI Skew 0.03x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact REPL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $21.41 · IV 88.6%

REPL Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($2,141)

Compare $2,141 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 88.6% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $21 / $25 Bull Call Spread

Buy 1x $21C · Sell 1x $25C · 32d

Net Entry $154 Debit
T+5d @ +5% Move +$26 (+17%)
Max Risk / Buffer $154 Capped
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $19 / $18 Bull Put Spread

Sell 4x $19P · Buy 4x $18P · 60d

Net Entry $232 Credit
Max Credit / Yield +$232 (+138.1% RoM)
Max Risk / Buffer -14.0% Cushion ($168 Mgn)
5d Edge & Liquidity 70% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $370.6M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($469M)
90D Engineering Disclosures 0 Published
REPL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRMD vs REPL Key Questions & Quantitative Answers

As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Replimune Group, Inc. (REPL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin), whereas REPL carries 34.8/100 (SELL) at $19.74 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. REPL 34.8/100 SELL) and 1.22β · 103% Vol risk profile, whereas REPL leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8); meanwhile REPL trades in a Markup technical trend (BREAKOUT options phase, RSI 59.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

REPL leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.01B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with REPL at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CRMD generates $1.01B in USD-normalized revenue versus N/A for REPL. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($469M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for REPL.

CRMD screens cheaper on headline valuation multiples. CRMD trades at 29.5x Forward P/E, 2.4x Trailing P/E, 3.32x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas REPL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus REPL (-115.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CRMD carries 53.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 2.32x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 103% Vol realized risk). By comparison, REPL carries 220.4% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (2.14β · 104% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.